Nextage Therapeutics Ltd (NXTG.TA)

ILA 104.5

(0.97%)

EBITDA Summary of Nextage Therapeutics Ltd

Nextage Therapeutics Ltd's latest annual EBITDA in 2023 was -4.02 Million ILS , up 31.81% from previous year.
Nextage Therapeutics Ltd's latest quarterly EBITDA in 2023 FY was N/A , up 31.81% from previous quarter.
Nextage Therapeutics Ltd reported an annual EBITDA of -5.9 Million ILS in 2022, up 7.16% from previous year.
Nextage Therapeutics Ltd reported an annual EBITDA of -7.58 Million ILS in 2021, up 50.69% from previous year.
Nextage Therapeutics Ltd reported a quarterly EBITDA of -2.53 Million ILA for 2023 Q2, up 11.12% from previous quarter.
Nextage Therapeutics Ltd reported a quarterly EBITDA of -1.32 Million ILA for 2023 Q4, up 47.71% from previous quarter.

Annual EBITDA Chart of Nextage Therapeutics Ltd (2023 - 2016)

Historical Annual EBITDA of Nextage Therapeutics Ltd (2023 - 2016)

Year	EBITDA	EBITDA Growth
2023	-4.02 Million ILS	31.81%
2022	-5.9 Million ILS	7.16%
2021	-7.58 Million ILS	50.69%
2020	-15.87 Million ILS	-665.22%
2019	-4.4 Million ILS	61.0%
2018	-4.32 Million ILS	15.74%
2017	-5.05 Million ILS	34.13%
2016	-7.78 Million ILS	0.0%

Year	EBITDA	EBITDA Growth
2023 FY	- ILS	31.81%
2023 Q2	-2.53 Million ILA	11.12%
2023 Q4	-1.32 Million ILA	47.71%
2022 Q4	-2.85 Million ILA	2.93%
2022 FY	- ILS	7.16%
2022 Q2	-2.93 Million ILA	0.0%
2021 Q2	-2.86 Million ILA	48.41%
2021 FY	- ILS	50.69%
2020 Q2	-1.43 Million ILA	14.56%
2020 Q4	-5.54 Million ILA	-287.29%
2020 FY	- ILS	-665.22%
2019 FY	- ILS	61.0%
2019 Q4	-1.67 Million ILA	34.71%
2019 Q2	-2.56 Million ILA	8.78%
2018 Q4	-2.81 Million ILA	0.0%
2018 FY	- ILS	15.74%
2017 FY	- ILS	34.13%
2016 FY	- ILS	0.0%

Peer EBITDA Comparison of Nextage Therapeutics Ltd

Name	EBITDA	EBITDA Difference
Cannabotech LTD	-14.81 Million ILA	72.822%